About

About SK Pharmteco Headquartered in Rancho Cordova, Calif., SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. SK pharmteco is comprised of six companies: SK Biotek Korea, SK Biotek Ireland, AMPAC Fine Chemicals, AMPAC Analytical Laboratories in the U.S., Yposkesi and the Center for Breakthrough Medicines. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group. For more on SK pharmteco, visit skpharmteco.com. About SK pharmteco Headquartered in Rancho Cordova, Calif., SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. SK pharmteco is comprised of six companies: SK Biotek Korea, SK Biotek Ireland, AMPAC Fine Chemicals, AMPAC Analytical Laboratories in the U.S., Yposkesi and the Center for Breakthrough Medicines. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group. For more on SK pharmteco, visit skpharmteco.com. SK pharmteco is a global contract development and manufacturing organization (CDMO) with production sites, research & development facilities, and analytical laboratories across the U.S., Europe, and South Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate. Established in 2019 by SK Inc., SK pharmteco is a global contract development and manufacturing organization (CDMO) with a strategically integrated network across the United States and Europe, complemented by operations in South Korea. Backed by the scale and financial strength of SK Group, the company provides the stability, long-term investment, and operational resilience biopharmaceutical partners require to advance complex therapies with confidence. SK pharmteco’s business is anchored in three core modalities: small molecules, peptides, and viral vectors, with a growing strategic emphasis on advanced therapies. Its viral vector platform represents a cornerstone of the organization’s future, offering end-to-end solutions across lentiviral (LVV), adeno-associated viral (AAV), and adenoviral (AdV) systems. From early development through commercial manufacturing, SK pharmteco delivers high-yield, scalable processes, integrated analytical and fill and finish capabilities, and regulatory-ready infrastructure designed to accelerate speed to market. With purpose-built viral vector facilities in the U.S. and Europe, SK pharmteco enables true regional execution for global programs, supporting supply chain resilience, regulatory alignment, and proximity to patients and sponsors. Its transatlantic footprint allows clients to seamlessly progress from clinical to commercial stages without disruption, ensuring continuity, efficiency, and reduced risk throughout the product lifecycle. A defining feature of SK pharmteco’s approach is its commitment to flexible, partnership-driven engagement. Through models such as milestone-based agreements and its “Partner-in-Plant” concept, the company works as an extension of its clients’ teams, offering adaptable capacity, transparency, and hands-on collaboration to meet evolving program needs. Across all modalities, SK pharmteco combines deep technical expertise with operational excellence, delivering consistent quality, robust regulatory compliance, and reliable execution. Its integrated platform is designed to support increasingly complex and multi-modality pipelines, positioning the company as a trusted partner for innovators advancing the next generation of therapies.